307 filings
8-K
BDSI
Biodelivery Sciences International Inc
22 Mar 22
Termination of a Material Definitive Agreement
5:09pm
8-K/A
BDSI
Biodelivery Sciences International Inc
15 Feb 22
Entry into a Material Definitive Agreement
4:54pm
8-K
BDSI
Biodelivery Sciences International Inc
14 Feb 22
Collegium to Acquire BioDelivery Sciences in an All-Cash Deal
8:21am
8-K
BDSI
Biodelivery Sciences International Inc
20 Jan 22
BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year Guidance
8:05am
8-K
BDSI
Biodelivery Sciences International Inc
21 Dec 21
Regulation FD Disclosure
12:00am
8-K
kysb4d
3 Nov 21
BioDelivery Sciences Reports Solid Third Quarter 2021 Results
8:06am
8-K
3u4s0c3r03x9tq
21 Oct 21
BioDelivery Sciences Appoints John Golubieski as Chief Financial Officer
8:16am
8-K
e67fja3 z0t99
27 Sep 21
Other Events
4:18pm
8-K
x04xyrsj
21 Sep 21
Regulation FD Disclosure
5:03pm
8-K
l5bxl3
9 Sep 21
BioDelivery Sciences International Completes Acquisition of ELYXYB™ for Acute Migraine Treatment in the U.S. and Canada
9:26am
8-K
czha6woo
4 Aug 21
BioDelivery Sciences Announces Agreement to Acquire U.S. and Canadian Rights to FDA-approved ELYXYB™ for the Acute Treatment of Migraine
4:53pm
8-K
ydm8f8 tn
4 Aug 21
BioDelivery Sciences Reports Second Quarter 2021 Results
8:07am
8-K
qweys9kyremk191c8ew
30 Jul 21
Submission of Matters to a Vote of Security Holders
4:03pm
8-K
3xdsivk8765
27 Jul 21
Other Events
2:23pm
8-K
et62z0 7gdew8072
7 Jul 21
Regulation FD Disclosure
8:31am
8-K
67ga3x031h8mgq5pcy
6 May 21
BioDelivery Sciences Reports First Quarter 2021 Results
8:09am
8-K
z0ht6n7f8 off
10 Mar 21
BioDelivery Sciences Reports Strong Q4 and Record Full-Year 2020 Results
8:05am
8-K
kcqjov 6q80uyn177
4 Dec 20
Departure of Directors or Certain Officers
5:13pm
8-K
n8dk2uc q0w
5 Nov 20
BioDelivery Sciences Reports Strong Q3 2020 Results
8:07am
8-K
4w4v4jgafpx8gph
27 Oct 20
Departure of Directors or Certain Officers
4:09pm